Role of fibrinolysis in excessive menstrual bleeding (Hebrew)

In 18 women suffering from excessive menstrual bleeding unrelated to organic conditions, a therapeutic trial with the antifibrinolytic agent aminomethyl cyclohexane carboxylic acid was carried out. The menstrual blood loss was measured spectrophotometrically in 65 treated and 60 untreated cycles. A standard oral daily dose of 3 g reduced blood loss from an average of 119.5±49.3 ml/cycle to 54.2±16.7 ml/cycle and duration of menstruation from 7.61±1.7 days to 4.61±0.8 days. Side effects were infrequent and not serious. The favorable results obtained by antifibrinolytic treatment support the view that local fibrinolysis plays a definite role in functional menorrhagia.